Valeant Pharmaceuticals Announces Award In Anacor Dispute

LAVAL, Quebec, Oct. 18, 2013 /CNW/ - Valeant Pharmaceuticals International, 
Inc. (NYSE: VRX and TSX: VRX) announced today the interim final award in its 
previously disclosed arbitration with Anacor Pharmaceuticals, Inc. to resolve 
a breach of contract dispute arising out of services provided by Dow 
Pharmaceutical Sciences, Inc., prior to its acquisition by Valeant.  As a 
result of the September 2013 arbitration hearing, Valeant has been ordered to 
make a one-time payment of $100 million in damages plus costs and fees to 
Anacor.  The arbitrator did not grant an injunction or ongoing royalty, which 
means that, while still subject to regulatory approval, nothing in the 
arbitrator's order prevents the launch of Jublia(®) (efinaconazole 10% 
topical solution).  As previously disclosed, Anacor had sought an award of at 
least $215 million plus injunctive relief. 
About Valeant Pharmaceuticals International, Inc. 
Valeant Pharmaceuticals International, Inc. (NYSE and TSX: VRX) is a 
multinational specialty pharmaceutical company that develops, manufactures and 
markets a broad range of pharmaceutical products primarily in the areas of 
dermatology, eye health, neurology, and branded generics.  More information 
about Valeant Pharmaceuticals International, Inc. can be found at 
www.valeant.com. 
Forward-looking Statements 
This press release may contain forward-looking statements, including, but not 
limited to, statements regarding the launch of Jublia®.  Jublia has not been 
approved by the U.S. Food and Drug Administration.  Forward-looking statements 
may generally be identified by the use of the words "anticipates," "expects," 
"intends," "plans," "should," "could," "would," "may," "will," "believes," 
"estimates," "potential," "target," or "continue" and variations or similar 
expressions.  These statements are based upon the current expectations and 
beliefs of management and are subject to certain risks and uncertainties that 
could cause actual results to differ materially from those described in the 
forward-looking statements.  These risks and uncertainties include, but are 
not limited to, the uncertainty associated with the launch of a new product 
and the risks and uncertainties discussed in the Company's most recent annual 
or quarterly report and detailed from time to time in Valeant's other filings 
with the Securities and Exchange Commission and the Canadian Securities 
Administrators, which factors are incorporated herein by reference.  Readers 
are cautioned not to place undue reliance on any of these forward-looking 
statements.  These forward-looking statements speak only as of the date 
hereof.  Valeant undertakes no obligation to update any of these 
forward-looking statements to reflect events or circumstances after the date 
of this press release or to reflect actual outcomes. 
Contact Information: Laurie W. Little 949-461-6002  laurie.little@valeant.com 
(Logo: http://photos.prnewswire.com/prnh/20101025/LA87217LOGO)
 

SOURCE  Valeant Pharmaceuticals International, Inc. 
http://www.valeant.com 
http://photos.prnewswire.com/prnh/20101025/LA87217LOGO 
To view this news release in HTML formatting, please use the following URL: 
http://www.newswire.ca/en/releases/archive/October2013/18/c5091.html 
CO: Valeant Pharmaceuticals International, Inc.
ST: Quebec
NI: HEA MTC LAW VERDICTS LAWVIEWS  
-0- Oct/18/2013 12:01 GMT
 
 
Press spacebar to pause and continue. Press esc to stop.